CO2023001561A2 - Combinaciones para el tratamiento de cáncer - Google Patents

Combinaciones para el tratamiento de cáncer

Info

Publication number
CO2023001561A2
CO2023001561A2 CONC2023/0001561A CO2023001561A CO2023001561A2 CO 2023001561 A2 CO2023001561 A2 CO 2023001561A2 CO 2023001561 A CO2023001561 A CO 2023001561A CO 2023001561 A2 CO2023001561 A2 CO 2023001561A2
Authority
CO
Colombia
Prior art keywords
combinations
compound
relates
cancer
treatment
Prior art date
Application number
CONC2023/0001561A
Other languages
English (en)
Inventor
Gisela Schwab
Christian Scheffold
Colin Chong
Ssucheng Jeff Hsu
Peter Lamb
Peiwen Yu
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of CO2023001561A2 publication Critical patent/CO2023001561A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a combinaciones que comprenden un inhibidor de punto de control y un inhibidor de c-Met, el Compuesto 1. La invención también se refiere a formas cristalinas de la base libre del Compuesto 1, así como también formas cristalinas de sales del Compuesto 1, en combinación con un inhibidor de punto de control. La invención también se refiere una composición farmacéutica que comprende estas combinaciones. La invención además se refiere a métodos para tratar un cáncer administrando el Compuesto 1 como un agente único o una combinación descrita en este documento.
CONC2023/0001561A 2020-07-31 2023-02-14 Combinaciones para el tratamiento de cáncer CO2023001561A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063059601P 2020-07-31 2020-07-31
US202063113556P 2020-11-13 2020-11-13
US202163148921P 2021-02-12 2021-02-12
PCT/US2021/043699 WO2022026706A1 (en) 2020-07-31 2021-07-29 Combinations for the treatment of cancer

Publications (1)

Publication Number Publication Date
CO2023001561A2 true CO2023001561A2 (es) 2023-02-16

Family

ID=77431400

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0001561A CO2023001561A2 (es) 2020-07-31 2023-02-14 Combinaciones para el tratamiento de cáncer

Country Status (16)

Country Link
US (1) US20230301979A1 (es)
EP (1) EP4188376A1 (es)
JP (1) JP2023536264A (es)
KR (1) KR20230059792A (es)
CN (1) CN116437954A (es)
AU (1) AU2021318134A1 (es)
BR (1) BR112023001792A2 (es)
CA (1) CA3186517A1 (es)
CL (1) CL2023000289A1 (es)
CO (1) CO2023001561A2 (es)
CR (1) CR20230052A (es)
IL (1) IL300151A (es)
MX (1) MX2023001298A (es)
PE (1) PE20231369A1 (es)
TW (1) TW202220654A (es)
WO (1) WO2022026706A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3088200A1 (en) * 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
WO2023172917A1 (en) * 2022-03-07 2023-09-14 Sanofi-Aventis U.S. Llc Use of isatuximab in combination with other agents for the treatment of multiple myeloma
WO2023196899A2 (en) * 2022-04-08 2023-10-12 Global Cancer Technology Methods and products to screen and treat glioblastoma multiforme and other cancers, including breast cancers, using a combination of pi3kinase inhibitors with checkpoint inhibitors
WO2024086563A1 (en) * 2022-10-19 2024-04-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Therapeutic methods with target-linked small molecules and anti-target car t cells
CN117285533B (zh) * 2023-11-24 2024-01-30 四川省医学科学院·四川省人民医院 CD47/SIRPα小分子抑制剂及其应用和抗肿瘤药物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2886433C (en) 2012-10-04 2022-01-04 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
MX2015015037A (es) 2013-05-02 2016-07-08 Anaptysbio Inc Anticuerpos dirigidos contra la proteina muerte programada-1 (pd-1).
JP2019529476A (ja) * 2016-09-27 2019-10-17 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｎ−（４−（６，７−ジメトキシキノリン−４−イルオキシ）フェニル）−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドを用いた尿路上皮癌及び他の尿生殖器悪性腫瘍の治療方法
MX2019008032A (es) * 2017-01-20 2019-12-16 Exelixis Inc Combinaciones de cabozantinib y atezolizumab para tratar cancer.
CA3088200A1 (en) * 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
KR20210102381A (ko) 2018-12-13 2021-08-19 엑셀리시스, 인코포레이티드 키나아제 억제제의 결정질 형태 및 염 형태

Also Published As

Publication number Publication date
JP2023536264A (ja) 2023-08-24
WO2022026706A1 (en) 2022-02-03
KR20230059792A (ko) 2023-05-03
CN116437954A (zh) 2023-07-14
AU2021318134A1 (en) 2023-03-02
CA3186517A1 (en) 2022-02-03
BR112023001792A2 (pt) 2023-04-11
CR20230052A (es) 2023-04-11
TW202220654A (zh) 2022-06-01
EP4188376A1 (en) 2023-06-07
CL2023000289A1 (es) 2023-09-01
US20230301979A1 (en) 2023-09-28
MX2023001298A (es) 2023-02-22
IL300151A (en) 2023-03-01
PE20231369A1 (es) 2023-09-07

Similar Documents

Publication Publication Date Title
CO2023001561A2 (es) Combinaciones para el tratamiento de cáncer
CL2023000847A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
CL2021002965A1 (es) Compuestos antivirales que contienen nitrilo.
ECSP21080535A (es) Compuestos y métodos para el tratamiento de covid-19
CR20190252A (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes
CL2019001079A1 (es) Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina.
UY39027A (es) Uso de favipiravir en el tratamiento de la infección por coronavirus
CL2020002512A1 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak.
CL2023002383A1 (es) Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d
CL2020002544A1 (es) Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
CO2022000481A2 (es) Inhibidores de enzimas
CO2022000270A2 (es) Inhibidores de enzimas
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
CL2021000030A1 (es) Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales
AR122352A1 (es) Un esteroide c21-n-pirazolilo 19-nor c3,3 disustituido y métodos de uso de este
CO2022000266A2 (es) Inhibidores de enzimas
CL2021001976A1 (es) Tratamiento de lesiones cutáneas y prurito en pacientes con prurigo nodular
CO2021004681A2 (es) Uso de reboxetina para el tratamiento de narcolepsia
CL2023000943A1 (es) Formas cristalinas de un compuesto farmacéutico.
BR112023021913A2 (pt) Tratamento de câncer com inibidor de raf
BR112017014914A2 (pt) terapia combinada para hipertensão pulmonar
AR123227A1 (es) Terapias combinadas para su uso en el tratamiento del cáncer
PE20220250A1 (es) Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma
AR108792A1 (es) Composiciones que comprenden timolol